Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Front-Line Therapy with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) Followed by 2 Years of Rituximab Maintenance for Follicular Lymphoma (FL) Is Associated with Excellent Outcomes and Improved Progression-Free Survival (PFS) In Comparison to No Maintenance

Alden A. Moccia, Paul Hoskins, Richard Klasa, Kerry J. Savage, Tamara Shenkier, Graham W. Slack, Randy D. Gascoyne, Joseph M. Connors, Laurie H. Sehn

Blood (2010) 116 (21): 1803.

https://doi.org/10.1182/blood.V116.21.1803.1803

Published: 2010

Journal Articles

Outcome of Patients with Chemotherapy Refractory and Early Progressive Diffuse Large B Cell Lymphoma After R-CHOP Treatment

Felicitas Hitz, Joseph M. Connors, MD, Randy D. Gascoyne, MD, Paul Hoskins, Alden A. Moccia, Kerry Joanne Savage, MD, BSc, MSc, Laurie H. Sehn, MD, MPH, Tamara Shenkier, Richard Klasa, MD, CM, FRCP(C)

Blood (2010) 116 (21): 1751.

https://doi.org/10.1182/blood.V116.21.1751.1751

Published: 2010

Journal Articles

Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is An Effective and Well-Tolerated out-Patient Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL)

Alden A. Moccia, Felicitas Hitz, Paul Hoskins, Richard Klasa, Maryse Power, Kerry J. Savage, Tamara Shenkier, John Shepherd, Brian Skinnider, Graham W. Slack, Kevin Song, Randy D. Gascoyne, Joseph M. Connors, Laurie Sehn

Blood (2010) 116 (21): 113.

https://doi.org/10.1182/blood.V116.21.113.113

Published: 2010

Journal Articles

FDG-PET Scan Guided Consolidative Radiation Therapy Optimizes Outcome In Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) with Residual Abnormalities on CT Scan Following R-CHOP

Laurie H. Sehn, MD, MPH, Paul Hoskins, MD, Richard Klasa, MD, Tamara Shenkier, MD, Randy D. Gascoyne, MD, Francois Benard, MD, Don Wilson, MD, James Morris, MD, Tom Pickles, MD, Joseph M. Connors, MD, Kerry J. Savage, MD

Blood (2010) 116 (21): 854.

https://doi.org/10.1182/blood.V116.21.854.854

Published: 2010

Journal Articles

Hodgkin Lymphoma Patients with Stage II B or Stage II Bulky Disease Have Advanced Disease and Should Not Be Included In Limited Stage Trials

Joseph M. Connors, MD, Randy D. Gascoyne, MD, Paul Hoskins, MD, James Morris, MD, Tom Pickles, MD, FRCPC, Laurie Sehn, MD, MPH, Tamara Shenkier, MD, Richard Klasa, MD, CM, FRCP(C), Nicholas Voss, MD, Kerry Joanne Savage, MD, BSc, MSc

Blood (2010) 116 (21): 417.

https://doi.org/10.1182/blood.V116.21.417.417

Published: 2010

Journal Articles

The International Prognostic Factor Project Score (IPS) in Advanced Stage Hodgkin Lymphoma Has Limited Utility in Patients Treated in the Modern Era.

Moccia A. Moccia, Jane Donaldson, Mukesh Chhanabhai, Paul Hoskins, Richard Klasa, Kerry J. Savage, Tamara Shenkier, Brian Skinnider, Randy D. Gascoyne, Joseph M. Connors, Laurie H. Sehn

Blood (2009) 114 (22): 1554.

https://doi.org/10.1182/blood.V114.22.1554.1554

Published: 2009

Journal Articles

R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines.

Alden A. Moccia, Kimberly Schaff, Paul Hoskins, Richard Klasa, Kerry J. Savage, Tamara Shenkier, Randy D. Gascoyne, Joseph M. Connors, Laurie H. Sehn

Blood (2009) 114 (22): 408.

https://doi.org/10.1182/blood.V114.22.408.408

Published: 2009

Journal Articles

FDG-PET Guided Consolidative Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma with Residual Abnormalities on Post Chemotherapy CT Scan.

Kerry J. Savage, MD, MSc, Joseph M. Connors, MD, Don Wilson, MD, Richard Klasa, MD, Tamara Shenkier, MD, Paul Hoskins, MD, Nicholas Voss, MD, Laurie H. Sehn, MD

Blood (2007) 110 (11): 213.

https://doi.org/10.1182/blood.V110.11.213.213

Published: 2007

Journal Articles

Prognostic Utility of Extranodal Disease Involvement in Diffuse Large B-Cell Lymphoma in Patients Treated with R-CHOP.

David Hui, MD, MSc, Jane Donaldson, Paul Hoskins, MD, Richard Klasa, MD, Kerry J. Savage, MD, MPH, Tamara Shenkier, MD, Randy D. Gascoyne, MD, Joseph M. Connors, MD, Laurie Sehn, MD, MPH

Blood (2007) 110 (11): 1563.

https://doi.org/10.1182/blood.V110.11.1563.1563

Published: 2007

Journal Articles

Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) Patients with a Negative Pet Scan Following Three Cycles of R-CHOP Can Be Effectively Treated with Abbreviated Chemoimmunotherapy Alone.

Laurie H. Sehn, MD, MPH, Kerry J. Savage, MD, Paul Hoskins, MD, Richard Klasa, MD, Tamara Shenkier, MD, Nicholas Voss, MD, Don Wilson, MD, Joseph M. Connors, MD

Blood (2007) 110 (11): 787.

https://doi.org/10.1182/blood.V110.11.787.787

Published: 2007

Journal Articles

Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP-R Can Be Predicted by Stage and Serum Lactate Dehydrogenase (LDH) Level.

Laurie H. Sehn, MD, MPH, Mukesh Chhanabhai, MD, Karamjit Gill, MD, Paul Hoskins, MD, Richard Klasa, MD, Kerry J. Savage, MD, Tamara Shenkier, MD, Judy Sutherland, MD, Randy D. Gascoyne, MD, Joseph M. Connors, MD

Blood (2006) 108 (11): 2739.

https://doi.org/10.1182/blood.V108.11.2739.2739

Published: 2006

Journal Articles

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Laurie H. Sehn, Brian Berry, Mukesh Chhanabhai, Catherine Fitzgerald, Karamjit Gill, Paul Hoskins, Richard Klasa, Kerry J. Savage, Tamara Shenkier, Judy Sutherland, Randy D. Gascoyne, Joseph M. Connors

Blood (2006) 109 (5): 1857–1861.

https://doi.org/10.1182/blood-2006-08-038257

Published: 2006

Journal Articles

Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP).

Laurie H. Sehn, MD, MPH, Mukesh Chhanabhai, MD, Catherine Fitzgerald, MD, Karamjit Gill, MD, Paul Hoskins, MD, Richard Klasa, MD, Kerry Savage, MD, Tamara Shenkier, MD, Judy Sutherland, MD, Kenneth Wilson, MD, Randy D. Gascoyne, MD, Joseph M. Connors, MD

Blood (2005) 106 (11): 492.

https://doi.org/10.1182/blood.V106.11.492.492

Published: 2005

Journal Articles

Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma

Randy D. Gascoyne, Sheryle A. Adomat, Stanislaw Krajewski, Maryla Krajewska, Douglas E. Horsman, Anthony W. Tolcher, Susan E. O'Reilly, Paul Hoskins, Andrew J. Coldman, John C. Reed, Joseph M. Connors

Blood (1997) 90 (1): 244–251.

https://doi.org/10.1182/blood.V90.1.244

Published: 1997

NARROW

Front-Line Therapy with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) Followed by 2 Years of Rituximab Maintenance for Follicular Lymphoma (FL) Is Associated with Excellent Outcomes and Improved Progression-Free Survival (PFS) In Comparison to No Maintenance

Outcome of Patients with Chemotherapy Refractory and Early Progressive Diffuse Large B Cell Lymphoma After R-CHOP Treatment

Gemcitabine, Dexamethasone, and Cisplatin (GDP) Is An Effective and Well-Tolerated out-Patient Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL)

FDG-PET Scan Guided Consolidative Radiation Therapy Optimizes Outcome In Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma (DLBCL) with Residual Abnormalities on CT Scan Following R-CHOP

Hodgkin Lymphoma Patients with Stage II B or Stage II Bulky Disease Have Advanced Disease and Should Not Be Included In Limited Stage Trials

The International Prognostic Factor Project Score (IPS) in Advanced Stage Hodgkin Lymphoma Has Limited Utility in Patients Treated in the Modern Era.

R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines.

FDG-PET Guided Consolidative Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma with Residual Abnormalities on Post Chemotherapy CT Scan.

Prognostic Utility of Extranodal Disease Involvement in Diffuse Large B-Cell Lymphoma in Patients Treated with R-CHOP.

Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) Patients with a Negative Pet Scan Following Three Cycles of R-CHOP Can Be Effectively Treated with Abbreviated Chemoimmunotherapy Alone.

Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP-R Can Be Predicted by Stage and Serum Lactate Dehydrogenase (LDH) Level.

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

Revised International Prognostic Index (R-IPI) Is a Better Predictor of Outcome Than the Standard IPI for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab and CHOP (R-CHOP).

Prognostic Significance of Bcl-2 Protein Expression and Bcl-2 Gene Rearrangement in Diffuse Aggressive Non-Hodgkin's Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only